Serotonin 1A Agonists and Cognition in Schizophrenia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00178971
Recruitment Status :
First Posted : September 15, 2005
Last Update Posted : June 7, 2017
National Alliance for Research on Schizophrenia and Depression
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.
Condition or disease
Drug: adjunctive treatment with buspironeDrug: placebo
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects must meet all of the following criteria to be eligible for participation in the current research study.
Subjects will be males and females between 18-65 years of age;
Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
The subjects or their legal guardian must sign the informed consent;
Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months
Subjects who are pregnant or lactating
Subjects who have brain damage and/or neurological disorders